GlycoMimetics (GLYC) News Today $0.22 -0.01 (-2.55%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.comApril 15 at 1:43 AM | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.comApril 8, 2025 | americanbankingnews.comCrescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology TherapeuticsApril 3, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight RecommendationMarch 22, 2025 | msn.comCantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight RecommendationMarch 22, 2025 | msn.comCrescent Biopharma initiated with an Overweight at Cantor FitzgeraldMarch 22, 2025 | markets.businessinsider.comAcute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 7, 2025 | theglobeandmail.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of ShareholdersMarch 5, 2025 | prnewswire.comCrescent Biopharma to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comUS Penny Stocks To Watch In February 2025February 20, 2025 | finance.yahoo.comTop 5 Biotech Stocks That Got Most Retail Buzz Last WeekFebruary 17, 2025 | msn.comGlycoMimetics adjusts merger terms with Crescent BiopharmaFebruary 15, 2025 | msn.comGlycoMimetics executives to depart amid merger plansFebruary 1, 2025 | msn.comCrescent Biopharma to Present at Jefferies London Healthcare Conference 2024November 12, 2024 | prnewswire.comGlycoMimetics and Crescent Biopharma Merger AdvancesNovember 9, 2024 | markets.businessinsider.comGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNovember 7, 2024 | finance.yahoo.comINVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYCNovember 5, 2024 | globenewswire.comINVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYCNovember 3, 2024 | prnewswire.comGlycoMimetics options imply 8.8% move in share price post-earningsNovember 2, 2024 | markets.businessinsider.comGLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYCNovember 1, 2024 | tmcnet.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementOctober 31, 2024 | msn.comGlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpointOctober 30, 2024 | markets.businessinsider.comGlycoMimetics Shares Are Soaring Tuesday: Here's WhyOctober 30, 2024 | msn.comGlycoMimetics Announces Merger with Crescent BiopharmaOctober 30, 2024 | finance.yahoo.comShareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public ShareholdersOctober 29, 2024 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of ShareholdersOctober 29, 2024 | prnewswire.comGLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to ShareholdersOctober 29, 2024 | businesswire.comGlycoMimetics (NASDAQ:GLYC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comGlycoMimetics Inc (GKO.DU)September 20, 2024 | sg.finance.yahoo.comGlycoMimetics Inc (GLYC)August 31, 2024 | investing.comGlycoMimetics (GLYC) Earnings Dates & ReportsAugust 13, 2024 | investing.comGlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Public Equities L.P. Invus Sells 61,488 SharesAugust 10, 2024 | insidertrades.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)August 9, 2024 | markets.businessinsider.comGlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells $31,259.37 in StockAugust 8, 2024 | insidertrades.comGlycoMimetics, Inc. (GLYC) Stock Price, News, Quote & History - Yahoo FinanceAugust 6, 2024 | ca.finance.yahoo.comPublic Equities L.P. Invus Sells 63,564 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) StockAugust 6, 2024 | insidertrades.comInsider Selling: GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells 258,335 Shares of StockJuly 31, 2024 | insidertrades.comTD Cowen Downgrades GlycoMimetics (GLYC)July 27, 2024 | msn.comGlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold RatingJuly 26, 2024 | markets.businessinsider.comGlycoMimetics to cut workforce by about 80% in corporate restructuring planJuly 25, 2024 | msn.comGlycoMimetics Shares Drop 27% After Restructuring Plan, Job CutsJuly 25, 2024 | marketwatch.comGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanJuly 25, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Insider Buys $47,500.00 in StockJune 25, 2024 | insidertrades.comGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)June 4, 2024 | businesswire.comGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024May 29, 2024 | businesswire.comPipeline Moves: Phase III AML trial fails to meet primary endpointMay 28, 2024 | finance.yahoo.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 10, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 9, 2024 | msn.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 8, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 7, 2024 | msn.com Remove Ads Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Media Mentions By Week GLYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLYC News Sentiment▼0.620.79▲Average Medical News Sentiment GLYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLYC Articles This Week▼21▲GLYC Articles Average Week Remove Ads Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alto Neuroscience News Renovaro News ZIVO Bioscience News Metagenomi News Ikena Oncology News Pyxis Oncology News Kronos Bio News Gain Therapeutics News Oncolytics Biotech News Verrica Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLYC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLYC Stock Free GLYC Stock Alerts